ClinicalTrials.gg
RecruitingNCT06820905HYFERUpdated Nov 10, 2026

Hyperinflammation and Hyperferritinemia in Critically Ill Patients

An observational study in Critical Illness, Sepsis and Hyperferritinemia, sponsored by Charles University, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionSepsisRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Charles University, Czech Republic · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingFirst site in Czechia+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,962
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Sepsis with a site in Czechia — 4 open to participants now, 5 under way, none of them phase 3. Sepsis · Czechia.

Planned enrollment
Largest of 11
1,962 · median 200
Started
2026
with 1 other
Observational
11 of 28
2 open now
Registered
26th of 28
by date
Lead sponsor
4 of 28
Charles University, Czech Republic

Among the 28 studies in Sepsis with a site in Czechia, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, and was the 26th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 28 studies in Sepsis with a site in Czechia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Sepsis with a site in Czechia, or all of them as a file.
02

Study summary

Analysing trajectory of critically ill patients with signs of hyperinflammation

03

Conditions studied

  • Critical Illness
  • Sepsis
  • Hyperferritinemia
  • Hyperinflammatory Syndrome

Browse trials for

Keywords

  • criticall illness
  • sepsis
  • ferritin
  • hyperinflammatory syndrome
  • sepsis phenotype
04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 1,962 is above the median of 150 across 1,166 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

critically ill patients; mix-cases medical ICU population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • critically ill patients
  • admission between 01.01.2020 and 31.12.2024 (5yrs)

Exclusion criteria

Exclusion Criteria:

  • none
06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,962 participants (estimated)
Patient registry
No

Groups and cohorts

  • critically ill patients

    critically ill patients admitted to ICU between 01.01.2020 and 31.12.2024

07

What researchers measure

Primary outcomes

  1. hyperferritinemia

    trajectory of critically ill patients with significant hyperferritinemia and with regard to its dynamics; ferritin value cutt-off

    Time frame: 2025

Secondary outcomes

  1. etiology and association of hyperferritinemia

    etiology and association of hyperferritinemia with infectioius a non-infectious diseases/conditions

    Time frame: 2025

  2. mortality a morbidity

    mortality a morbidity of patients with significant hyperferritinemia

    Time frame: 2025

  3. treatment strategy

    association of hyperferritinemia and treatment strategy

    Time frame: 2025

  4. stratification

    patient stratification according to hyperferritinemia/hyperinflammation

    Time frame: 2025

08

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine and Teaching Hospital, Charles University
    Pilsen, Czech Republic 30460, Czechia
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Clinical study report

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Feb 2025 → Oct 2026, primary completion Jun 2025 → Dec 2027 and completion Nov 2025 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 11, 2025
StartActual
Oct 1, 2026was Feb 2025
Primary completionEst.
Dec 31, 2027was Jun 2025
CompletionEst.
Jun 30, 2028was Nov 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added, 1 site removed — first site in Czechia; no longer in Czech Republic
Show site
  • Faculty of Medicine and Teaching Hospital, Charles University · Pilsen, Czechia
Show 1 removed
  • Faculty of Medicine and Teaching Hospital, Charles University · Pilsen, Czech Republic
Nov 10, 2026
Start date
Feb 20, 2025→Oct 1, 2026 (actual)
Nov 10, 2026
Primary completion
Jun 30, 2025→Dec 31, 2027
Nov 10, 2026
Study completion
Nov 30, 2025→Jun 30, 2028
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed — first site in Czechia; no longer in Czech Republic
    Show site
    • Faculty of Medicine and Teaching Hospital, Charles University · Pilsen, Czechia
    Show 1 removed
    • Faculty of Medicine and Teaching Hospital, Charles University · Pilsen, Czech Republic
    Start date Feb 20, 2025→Oct 1, 2026 (now actual)
    Primary completion Jun 30, 2025→Dec 31, 2027
    Study completion Nov 30, 2025→Jun 30, 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06820905
Responsible party
Thomas Karvunidis (Principal investigator, Charles University, Czech Republic) — Principal investigator
First posted
Feb 11, 2025
Start date
Oct 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Thomas Karvunidis, MD, PhD
Contact
karvunidist@fnplzen.cz
+420776160620
Thomas Karvunidis, MD, PhD
principal investigator · Faculty of Medicine and Teaching Hospital, Charles University, Pilsen, Czech Republic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion